Capital Markets

Capital Markets

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Key Contacts

Meet Our Team

Areas of Focus

Expand All Collapse All

Initial Public Offerings: A Practical Guide to Going Public

Initial Public Offerings: “A Practical Guide to Going Public” is the ultimate roadmap to the IPO process. Hailed by executives, entrepreneurs, general counsel, investment bankers and venture capitalists alike as the definitive IPO guide, this comprehensive resource charts every twist and turn on the IPO journey and provides battle-tested, real-world advice on how to navigate the roadblocks.

2020 IPO Report—A Detailed IPO Market Review and Outlook



  • Initial Public Offerings – Issuers

    Representing Acacia, Aileron Therapeutics, Apellis Pharmaceuticals, Arsanis, Arvinas, Blue Apron, Casa Systems, Constellation Pharmaceuticals, Editas Medicine, EverQuote, Kala Pharmaceuticals, Spring Bank Pharmaceuticals, Stealth BioTherapeutics, Syros Pharmaceuticals and Translate Bio in initial public offerings.
  • Initial Public Offerings – Underwriters

    Representing the underwriters in the initial public offerings of Adaptimmune Therapeutics, Biotie Therapies, CarGurus, ChannelAdvisor, Entasis Therapeutics, HubSpot, Imprivata, MacroGenics, ProQR Therapeutics, Rhythm Pharmaceuticals, TCR² Therapeutics, Xeris Pharmaceuticals and Zynerba Pharmaceuticals.
  • Follow-On Public Offerings

    Representing Acacia, Achillion Phamaceuticals, Agios Pharmaceuticals, Apellis Pharmaceuticals, Argos Therapeutics, Casa Systems, Casella Waste Systems, Catabasis Pharmaceuticals, Editas Medicine, Epizyme, Franklin Street Properties, Genpact, Idera Pharmaceuticals, Infinity Pharmaceuticals, Karyopharm Therapeutics, Medtronic, Nabriva, Nightstar Therapeutics, Ocular Therapeutix, Spark Therapeutics, Tetraphase Pharmaceuticals, Thermo Fisher Scientific and Voyager Therapeutics in follow-on public offerings.
  • Rule 144A Placements

    Representing Akamai Technologies, Bottomline Technologies, Entegris, Fortive, Huntington Ingalls Industries, PTC Therapeutics, Red Hat and WEX in Rule 144A placements of convertible and senior note offerings.
  • Public Offerings of Senior Notes, Convertible Notes, Mandatory Convertible Preferred Stock and Preferred Stock

    Representing Analog Devices, Danaher, Discovery, Entegris, Federal Agricultural Mortgage Corporation, Fortive, Intercept Pharmaceuticals, Karyopharm Therapeutics, Medtronic, PerkinElmer, State Street and Thermo Fisher Scientific in public offerings of senior notes.


  • Award Text

    Recognized Among the Nation's Best for Capital Markets

    Chambers USA


  • Award Text

    Named a First-Tier National Firm for Securities/Capital Markets Law

    U.S. News - Best Lawyers®


  • Award Text

    Named to the Top National Corporate Law Firms List

    Corporate Board Member

    2014, 2016, 2018

  • Chambers USA: America’s Leading Lawyers for Business – Ranked WilmerHale in Massachusetts for Capital Markets and in Massachusetts and Washington DC for Corporate/M&A.
  • Chambers Global – Recognized 34 WilmerHale lawyers and 27 practice areas in their 2020 edition.
  • Best Lawyers in America – Recognized 124 WilmerHale partners for 2020, naming 11 as “Lawyers of the Year.”
  • U.S. News - Best Lawyers® – In the 2010–2020 “Best Law Firms” rankings, our corporate, mergers and acquisitions, and venture capital law practices were ranked in the first tier nationally and in Boston, along with our corporate law practice also being ranked in the first tier in New York and Washington DC. Our securities/capital markets law practice was ranked first tier nationally and in Washington DC, and second tier in Boston. Our technology law practice was also ranked in the first tier in Boston and in the second tier nationally.
  • Corporate Board Member – In 2014, 2016 and 2018, WilmerHale was named to Top National Corporate Law Firms list, a comprehensive ranking of the top 25 firms in the nation. Results are based on law firm surveys and feedback from thousands of directors and general counsel.
  • LMG Life Sciences – Named WilmerHale the US Life Cycle Firm of the Year in 2017–2019 and among the shortlist from 2012–2019. LMG has also ranked the firm in its 2012–2019 editions in corporate, licensing and collaboration, M&A, venture capital and several other practice areas, and named 18 WilmerHale lawyers as “life sciences stars.”
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016–2018, an award recognizing the firm’s key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • Super Lawyers – Our corporate lawyers are consistently recognized as “Super Lawyers” and “Rising Stars” in multiple jurisdictions.

Insights & News